---
document_datetime: 2023-10-31 11:06:16
document_pages: 25
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tandemact-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: tandemact-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 13.7496403
conversion_datetime: 2025-12-28 09:12:37.075252
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tandemact

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0069/G            | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s) | 07/09/2023                          |                                             | SmPC, Labelling and PL           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0068            | C.I.7.b - Deletion of - a strength                                                                                                                                                                                                                                                                                                | 11/07/2023   |            | SmPC, Labelling and PL           |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------|
| PSUSA/2417/ 202107 | Periodic Safety Update EU Single assessment - glimepiride / pioglitazone hydrochloride, metformin / pioglitazone, pioglitazone                                                                                                                                                                                                    | 10/03/2022   | n/a        |                                  | PRAC Recommendation - maintenance |
| T/0066             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                               | 03/06/2021   | 24/06/2021 | SmPC, Labelling and PL           |                                   |
| WS/1979/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation A.1 - Administrative change - Change in the name and/or address of the MAH | 04/02/2021   | 24/06/2021 | SmPC, Annex II, Labelling and PL |                                   |
| IAIN/0064          | B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer                                                                                                                                           | 10/07/2020   | n/a        |                                  |                                   |
| IA/0063            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or                                                                                                                        | 30/04/2020   | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

|           | manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                       |                              |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------|
| WS/1680   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of an updated RMP (version 27.1) in order to update and consolidate within a single RMP the RMPs for Pioglitazone, Pioglitazone/Metformin fixed dose combination (FDC) and Pioglitazone/Glimepiride FDC. The list of safety concerns has also been reviewed and consolidated RMP version updated with information agreed/approved as part of the PSUR procedure (EMEA/H/C/PSUSA/00002417/201807) with regards to discontinuation of pioglitazone aRMMs. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH | 28/11/2019 | n/a        |                       | where significant assessment |
| IB/0062/G | This was an application for a group of variations. B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings B.II.b.1.a - Replacement or addition of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 07/11/2019 | 19/10/2020 | SmPC, Annex II and PL |                              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| manufacturing site for the site B.II.b.1.b - Replacement manufacturing site for the site B.II.b.1.e - Replacement manufacturing site for the manufacturing operation(s) release, batch control, primary packaging, for non-sterile B.II.b.2.c.2 - Change to arrangements and quality Including batch control/testing B.II.b.3.a - Change in the the finished or intermediate in the manufacturing process B.II.b.4.a - Change in the size ranges) of the finished compared to the originally B.II.b.5.z - Change to in-process applied during the manufacture product - Other variation B.II.e.1.a.1 - Change in finished product - Qualitative composition - Solid pharmaceutical B.II.e.3.b - Change in test immediate packaging of changes to a test procedure or addition) B.II.b.5.z - Change to in-process applied during the manufacture   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IG/1101            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                  | 08/08/2019   | n/a        |                                  |                                                                                                                                                       |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2417/ 201807 | Periodic Safety Update EU Single assessment - glimepiride / pioglitazone hydrochloride, metformin / pioglitazone, pioglitazone                                                                                                                                                                                                                                                                                                                 | 28/03/2019   | 27/05/2019 | Annex II                         | Please refer to PSUSA-00002417-201807 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| WS/1443            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                   | 20/09/2018   | 27/05/2019 | SmPC, Annex II, Labelling and PL |                                                                                                                                                       |
| WS/1388/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of | 25/05/2018   | n/a        |                                  |                                                                                                                                                       |
| WS/1294            | This was an application for a variation following a worksharing procedure according to Article 20 of                                                                                                                                                                                                                                                                                                                                           | 14/12/2017   | n/a        |                                  |                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                    | Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                     |            |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1138            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 11/05/2017 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| PSUSA/2417/ 201607 | Periodic Safety Update EU Single assessment - glimepiride / pioglitazone hydrochloride, metformin / pioglitazone, pioglitazone                                                                                                                                                                                                                             | 09/03/2017 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IG/0766            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                              | 02/02/2017 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| WS/0991            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                | 26/01/2017 | n/a | Pioglitazone_5018 is a nested case-control study to further investigate a potential association between pioglitazone use and prostate cancer, using the CPRD GOLD database. The study was specifically designed to evaluate the risk of prostate cancer with use of pioglitazone in male patients with T2DM.Additionally, data on the incidence of adjudicated prostate cancer in patients receiving pioglitazone in the long-term Insulin Resistance |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                 | Intervention after Stroke (IRIS) trial (IRIS Report) have also been provided. The results of this study did not show a statistically significant association between pioglitazone and prostate cancer. The MAH provided available histological data on cases of prostate cancer. Though the available data is very limited, the results of the histological data from all sources available to the MAH (Safety database, Pioglitazone_5018, PROactive Extension study and IRIS study) suggest that the majority of prostate cancers are prostatic adenocarcinomas in keeping with the common histological type seen in prostate cancer. Though the available data is very limited, there remain uncertainties in relation to any causal association between prostate cancer and pioglitazone therapy. The Marketing Authorisation Holder will continue to closely monitor this issue and will report   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0739/G | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or | 30/11/2016 | 10/11/2017 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                    | deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer   |            |            |                                  |                                                                                                                                                                                                                                                                                          |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0990            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                  | 13/10/2016 | n/a        |                                  |                                                                                                                                                                                                                                                                                          |
| R/0049             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                      | 21/07/2016 | 09/09/2016 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Tandemact in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                  |
| PSUSA/2417/ 201507 | Periodic Safety Update EU Single assessment - glimepiride / pioglitazone hydrochloride, metformin / pioglitazone, pioglitazone                                                                                                                                                                                                               | 01/04/2016 | 26/05/2016 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2417/201507.                                                                                                                                                |
| WS/0848            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of the section 4.4 of the SmPC based on results of two long-term observational cohort studies                                                                                           | 28/04/2016 | 09/09/2016 | SmPC and PL                      | As a result of this variation the Product information has been updated to reflect the fact that although some epidemiological studies have suggested a small increased risk of bladder cancer in diabetic patients treated with pioglitazone, not all of them identified a statistically |

<div style=\"page-break-after: always\"></div>

|         | assessing bladder cancer risk with pioglitazone. The RMP has been updated accordingly. Furthermore, minor editorial changes were introduced in the PI. In addition, the MAH took the opportunity to update the details of local representatives in the Package leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                              |            |     | significant increased risk.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------|
| WS/0875 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                            | 01/04/2016 | n/a |                               |
| WS/0827 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of final results from observational study PROactive together with post hoc analysis of KPNC and comprehensive review of the data on prostate cancer risk. The RMP is updated accordingly and RMP versions 22.1 of Actos, Glustin, Competact and Glubrava and RMP version 20.1 of Tandemact are acceptable. C.I.13 - Other variations not specifically covered | 25/02/2016 | n/a | n/a                           |

<div style=\"page-break-after: always\"></div>

|                    | elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IG/0652            | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/01/2016 | n/a |                                   |
| WS/0705            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To change the due date for reporting of the Pan- European multiple database bladder cancer risk characterisation study ER12-9433 from 30 December 2014 to 31 July 2015. In addition, an administrative change has been introduced to include mention of a Drug Utilization Study using the medical registries in Denmark (Pioglitazone 5019) and associated timelines. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing | 21/05/2015 | n/a |                                   |
| PSUSA/2417/ 201407 | Periodic Safety Update EU Single assessment - glimepiride / pioglitazone hydrochloride, metformin / pioglitazone, pioglitazone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12/03/2015 | n/a | PRAC Recommendation - maintenance |
| WS/0646            | This was an application for a variation following a worksharing procedure according to Article 20 of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 20/11/2014 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|         | Commission Regulation (EC) No 1234/2008. Submission of the study AD-4833-411, a study on the utilization of pioglitazone in clinical practice in the UK after the product information update in July 2011, and updated RMP in order to reflect the finalisation of the study. The MAH takes the occasion to implement in the RMP already agreed administrative information. The requested worksharing procedure leads to amendments to the Risk Management Plan (RMP). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                   |            |     |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/0647 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of the study 01-03-TL-OPI-524, Cohort Study of Pioglitazone and Bladder Cancer in Patients with Diabetes, and updated RMP in order to reflect the finalisation of the study. The MAH takes the occasion to implement in the RMP already agreed administrative information. The requested worksharing procedure proposed amendments to the Risk Management Plan (RMP). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 20/11/2014 | n/a |

<div style=\"page-break-after: always\"></div>

|           | of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                                  |     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----|
| WS/0609   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                           | 25/09/2014 | n/a        |                                  |     |
| WS/0541   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. The WSA submitted the final analysis report of the KPNC non-bladder malignancy study extension (AD4833-403) and an updated Risk Management Plan to reflect the final study results. The requested worksharing procedure proposed no amendments to the PI. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 25/09/2014 | n/a        |                                  | N/A |
| IB/0037/G | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer                                                                                                                                                                                                                                                                                                                            | 23/07/2014 | 08/07/2015 | SmPC, Annex II, Labelling and PL |     |

<div style=\"page-break-after: always\"></div>

|                    | responsible for batch release C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                               |            |            |             |                                                                                 |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------|
| PSUSA/2417/ 201307 | Periodic Safety Update EU Single assessment - glimepiride / pioglitazone hydrochloride, metformin / pioglitazone, pioglitazone                                                                                                                                                                                                                                             | 06/03/2014 | n/a        |             | PRAC Recommendation - maintenance                                               |
| IG/0401            | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                            | 11/02/2014 | n/a        |             |                                                                                 |
| PSUV/0033          | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                     | 19/09/2013 | 13/11/2013 | SmPC and PL | For further information please refer to: Tandemact-H-C- 680-Grounds PSUV-33-en. |
| WS/0413            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To introduce an alternative size for the immediate packaging of the active substance (pioglitazone). B.I.c.2.z - Change in the specification parameters and/or limits of the immediate packaging of the AS - Other variation | 19/09/2013 | n/a        |             |                                                                                 |
| IG/0307            | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                           | 04/06/2013 | n/a        |             |                                                                                 |

<div style=\"page-break-after: always\"></div>

| T/0030    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 25/03/2013   | 22/04/2013   | SmPC, Labelling and PL   | Transfer of the Marketing Authorisation to Takeda Pharma A/S, Denmark.                                                                                                                                                                                                                                                         |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0267/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition B.I.c.2.z - Change in the specification parameters and/or limits of the immediate packaging of the AS - Other variation                                                                                                                                                                                                                                                   | 12/02/2013   | n/a          |                          |                                                                                                                                                                                                                                                                                                                                |
| IG/0231   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 16/11/2012   | n/a          |                          |                                                                                                                                                                                                                                                                                                                                |
| WS/0324   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.8 of the SmPC, upon request by the CHMP following the assessment of the 25th PSUR for pioglitazone, in order to update the safety information regarding hypersensitivity and allergic reactions. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to make editorial changes in the SmPC and Package Leaflet, and to update the list of local representatives for the Portuguese representative in the Package Leaflet for Glustin. | 15/11/2012   | 14/01/2013   | SmPC and PL              | The following information was included in the SmPC as part of this procedure: Post-marketing reports of hypersensitivity and allergic reactions in patients treated with pioglitazone have been reported. These reactions include anaphylaxis, angioedema, and urticaria. The frequency of these adverse reactions is unknown. |

<div style=\"page-break-after: always\"></div>

|             | This variation followed a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH   |            |            |                        |                                                                                                                                                                                                                                        |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0179     | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                  | 30/05/2012 | n/a        |                        |                                                                                                                                                                                                                                        |
| IAIN/0025/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                       | 26/03/2012 | n/a        |                        |                                                                                                                                                                                                                                        |
| R/0023      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                           | 20/10/2011 | 02/03/2012 | SmPC, Labelling and PL | Based on the review of the available information the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered that the |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|          |                                                                                              |            |            | benefit risk profile of Tandemact continues to be favourable, but considers that its safety profile is to be closely monitored for the following reasons: The use of pioglitazone/glimepride is associated with a number of identified adverse events (cardiac failure, weight gain, macular oedema, hypoglycaemia, carcinogenicity in particular bladder cancer and bone fractures) as well as potential risks (hepatic events, rhabdomyolysis, anaphylactoid reactions, blood disorders, cerebrovascular ischaemia, cardiac ischaemia) to be closely monitored and to be reported in 6 monthly PSURs and included in the Risk Management Plan. With regard to the identified risk of bladder cancer, the CHMP has reviewed the totality of the available data on pioglitazone, including preclinical studies, clinical studies, post-marketing data and epidemiological studies within an Art. 20 referal procedure and concluded that the available data consistently identified a small increased risk of bladder cancer associated with the use of pioglitazone. Therefore, the CHMP decided that the MAH should continue to submit 6- monthly PSURs and the MAH should, based on pharmacovigilance grounds, submit one additional renewal application in 5 years time. During the renewal procedure, changes were made to the Product Information to bring it in line with the current EMA/QRD template, SmPC guideline and other relevant guidelines, which were reviewed by QRD and accepted by the CHMP. In addition, the list of local representatives in   |
|----------|----------------------------------------------------------------------------------------------|------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A20/0022 | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested the | 20/10/2011 | 22/12/2011 | Please refer to the CHMP Assessment Report: Revised Assessment Report for Actos, Glustin, Competact,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|           | CHMP to assess the safety concern of bladder cancer and its impact on the benefit-risk balance of the centrally authorised products containing pioglitazone. The European Commission requested the Committee to give its opinion as to whether measures are necessary to ensure the safe use of these medicinal products and specifically on whether the marketing authorisation should be maintained, varied, suspended or withdrawn.                                                                                                                          |            |            |                    | Glubrava, Tandemact Article 20 procedures (EMEA/H/C/0285/A-20/0046; EMEA/H/C/0286/A-20/0044; EMEA/H/C/0665/A-20/0030; EMEA/H/C/0893/A-20/0015; EMEA/H/C/0680/A-20/0022)                                                           |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0021/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS | 01/09/2010 | n/a        |                    |                                                                                                                                                                                                                                   |
| II/0020   | Update of SPC and Labelling Update of section 5.3 of the SPC upon request by CHMP following the assessment of FU2 033.3, to reflect the results of the mechanistic study in rats                                                                                                                                                                                                                                                                                                                                                                                | 18/02/2010 | 23/03/2010 | SmPC and Labelling | Prior to the initial submission of pioglitazone to EU regulatory authorities, 2 year bioassays in the rat and mouse determined pioglitazone treatment to be associated with urinary bladder tumours in the male rat. Pioglitazone |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| that was undertaken to investigate the mechanisms responsible for an increased incidence of hyperplasia and tumours of the urinary bladder epithelium in rats treated with pioglitazone for up to 2 years. In addition, the MAH table the opportunity to implement some minor changes in the labelling in line with the latest QRD template. Update of Summary of Product Characteristics and Labelling   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                       |            |            |                        | response is not considered to be the primary cause of the hyperplastic changes. The relevance to humans of the tumourigenic findings in the male rat cannot be excluded. There was no tumorige                                                                                                                                                                                                                                                                       |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0019  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                      | 01/09/2009 | n/a        | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0018 | Update of the Detailed Description of the Pharmacovigilance System (DDPS). Annex II has been updated in line with the QRD requirements for the Risk Management Plan and the Pharmacovigilance System including the new version number of the DDPS. Minor corrections were also included in the Summary of Product Characteristics. Update of DDPS (Pharmacovigilance) | 23/07/2009 | 31/08/2009 | SmPC and Annex II      | The MAH updated its Pharmacovigilance System and submitted therefore a type II variation. The CHMP considered that the Pharmacovigilance System as described by the MAH fulfils the requirements and provides adequate evidence that the MAH has the services of a qualified person responsible for pharmacovigilance and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country. |
| IB/0017 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                                                                                                                                                                                                            | 27/03/2009 | n/a        | SmPC                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0016 | IA_01_Change in the name and/or address of the marketing authorisation holder                                                                                                                                                                                                                                                                                         | 23/02/2009 | n/a        | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0015 | IB_17_a_Change in re-test period of the active substance                                                                                                                                                                                                                                                                                                              | 28/07/2008 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0014 | IB_17_a_Change in re-test period of the active substance                                                                                                                                                                                                                                                                                                              | 28/07/2008 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0012 | IB_25_a_01_Change to comply with Ph. -                                                                                                                                                                                                                                                                                                                                | 28/07/2008 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|         | compliance with EU Ph. - active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                        |                                                                                                                                                                                                         |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0013 | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 09/07/2008 | n/a        |                        |                                                                                                                                                                                                         |
| IA/0011 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 07/07/2008 | n/a        |                        |                                                                                                                                                                                                         |
| X/0006  | The new presentation consists in a new tablet strength (30 mg pioglitazone / 2 mg glimeperide). The active substances and the finished product are identical to the authorised strengths except for the strength. Relevant studies were submitted on bioequivalence and the influence of food. The available data supported this new strength application satisfactorily. No unknown safety issues arose during the assessment of this Annex II application for the line extension. The safety issues of pioglitazone and glimepiride apply to this 30mg/2mg pioglitazone/glimepiride strength. The product will be continuously followed in the future through the PSURs and the Follow-up measures agreed by the CHMP. Annex I_2.(c) Change or addition of a new | 24/01/2008 | 31/03/2008 | SmPC, Labelling and PL |                                                                                                                                                                                                         |
| II/0010 | Following a request from the CHMP, section 4.4 of Summary of Product Characteristics was updated in order to include a warning on the increased risk of haemolytic anaemia in patients with glucose-6-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 18/10/2007 | 11/12/2007 | SmPC and PL            | The Pharmacovigilance Working Party (PhVWP) performed a review of drugs that might induce an increased risk of haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. |

<div style=\"page-break-after: always\"></div>

|         | phosphate dehydrogenase (G6PD) deficiency. The Package Leaflet was updated accordingly. Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                                                                                                 |            |            |                       | Glibenclamide, a sulfonylurea agent, is known to be directly responsible for haemolytic anaemia in patients with G6PD deficiency. After the review of other sulphonylureas, the PhVWP was of the opinion that haemolytic anaemia in patients with G6PD deficiency is a class effect of sulfonylurea agents. The PhVWP and the CHMP considered that given a potential class effect, a warning statement should be added in the product information of all sulphonylurea agents. Therefore, the Marketing Authorisation Holder (MAH) for Tandemact was requested to submit this type II variation in order to include a warning regarding the increased risk of haemolytic anaemia in patients with G6PD deficiency taking glimepiride.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0009 | Update of section 4.3 of the Summary of Products Characteristics (SPC) to remove the contraindication for the use of pioglitazone in combination with insulin. Sections 4.4, 4.8 and 5.1 of the SPC have been consequently updated to add information on the risk of heart failure. The relevant sections of the Package Leaflet have been updated accordingly. Additionally, Annex II was updated to reflect the revision of the Risk Management Plan. Update of Summary of Product Characteristics and Package Leaflet | 20/09/2007 | 30/11/2007 | SmPC, Annex II and PL | The MAH submitted this Type II variation to remove the contraindication for the use of pioglitazone in combination with insulin, primarily as a result of clinical trial data from the completion of a large macrovascular outcome study of pioglitazone in patients with type 2 diabetes mellitus, known as 'PROactive' (protocol reference AD-4833/EC444), performed following a commitment made to the CPMP in June 2000. The MAH also submitted, as part of the present variation application, data from three efficacy and safety studies of pioglitazone used in combination with insulin. The main concern of the CHMP was the fact that both insulin and pioglitazone alone are associated with fluid                           |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                    |            |            |      | retention and heart failure. However, it appears that combination therapy with pioglitazone and insulin is associated with an increased risk of heart failure, but not an increase in mortality, in particular from the sequelae of heart failure. The degree of heart failure would most likely be mild, and could be monitored symptomatically or by weight gain. Therefore, the CHMP concluded that the exposure data presented was adequate to support the deletion of the contraindication with insulin, provided that the risk of heart failure is reflected in detail in the product information and in the Risk Management Plan. Section 4.3 of the Summary of Products Characteristics was updated to remove the contraindication for the use of pioglitazone in combination with insulin. Sections 4.4, 4.8 and 5.1 were consequently updated to add information on the risk of heart failure. The relevant sections of the   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0008 | Update of section 5.1 of the SPC to describe the results of a large macrovascular outcome study of pioglitazone in patients with type 2 diabetes mellitus (PROactive study). Section 4.4 has been updated to add information on the risk of heart failure, as per the results of the mentioned study. Update of Summary of Product Characteristics | 20/09/2007 | 30/11/2007 | SmPC | At the time of the original Marketing Authorisation of Actos (pioglitazone), the MAH committed to perform a large macrovascular outcome study of pioglitazone in patients with type 2 diabetes mellitus. The MAH submitted the results of this macrovascular outcome study (PROactive study). The PROactive study failed regarding it's pre-specified primary endpoint, and any benefit suggested by the secondary endpoint suggests an effect in a type 2 diabetic population with extensive disease and being treated concurrently with multiple anti-diabetic and cardiovascular medicines, and treated with 45mg of pioglitazone. As would be expected, there were increases in weight in the                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                        | pioglitazone group, and an increase in hypoglycaemia corresponding with better control of diabetes. There was also an increase in cardiac failure in the pioglitazone group. Although these were no new safety issues, the previous safety concerns relating to weigh gain, oedema and heart failure were confirmed. Although the PROactive study suggested that administration of pioglitazone was not associated with an increased cardiovascular risk, the study failed to document a clear benefit, and the safety concerns mentioned above remain, particularly in the context of the new indication of pioglitazone in combination with insulin. The CHMP agreed that some information on the PROactive study, which was a significant and well-conducted study, could be introduced in section 5.1 of the Summary of Product Characteristics.   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0005 | The MAH applied for the replacement of the primary packaging from 30 tablets and 90 tablets HPDE bottles to 14, 28, 30, 50, 90 and 98 tablets in aluminium/aluminium blisters. The MAH will not market any longer the HPDE bottle presentations. As a consequence the MAH also applied for changes in the formulation, changes in the manufacturing process and tests methods of the finished product. New presentation(s) | 20/09/2007 | 12/11/2007 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0004 | Update of the Summary of Product Characteristics (SPC) and Package Leaflet (PL) to include information on the risk of bone fractures in female patients treated with pioglitazone.                                                                                                                                                                                                                                         | 24/05/2007 | 27/08/2007 | SmPC and PL            | Further to the review of available information on increased incidence of fractures among female patients with type 2 diabetes taking a TZD, the CHMP was of the view that this issue should be further investigated and requested the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | Update of Summary of Product Characteristics and Package Leaflet                            |            |     | Marketing Authorisation Holder (MAH) to provide information on all cases of fractures in patients taking pioglitazone, as well as an overview of all clinical and non- clinical studies with glitazones in which bone metabolism was investigated or in which an effect on bone has been reported. Upon evaluation of the data provided by the MAH, the CHMP was of the view that there are theoretical reasons why thiazolidinediones could be associated with increased risk of fracture. Severity and duration of diabetes are risks factors for osteoporosis, and it is difficult to draw conclusions from the post-marketing data as fractures not surprisingly occur in older female patients. However, considering the clinical trial database, there appears to be a small but definite increased risk of fracture in the female patients treated with pioglitazone and analyses of the pooled data from controlled, double-blind, randomised, comparative clinical studies suggest a relative increase in fracture risk with time. Based on the available data, the CHMP requested the MAH to update the product information for Actos to reflect the risk of bone fractures. Sections \"Special warnings and precautions for use\" and \"Undesirable effects\" of the Summary of Product Characteristics (SPC) were updated with the available data from clinical trials regarding bone fractures and with a warning reflecting that the risk of fractures should be considered in the long-term care of women treated with pioglitazone.   |
|---------|---------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0007 | IA_28_Change in any part of primary packaging material not in contact with finished product | 15/06/2007 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|         | IA_36_ b_Change in shape or dimensions of the container/closure - other pharm. forms   |            |     |
|---------|----------------------------------------------------------------------------------------|------------|-----|
| IB/0003 | IB_10_Minor change in the manufacturing process of the active substance                | 20/04/2007 | n/a |
| IB/0002 | IB_10_Minor change in the manufacturing process of the active substance                | 20/04/2007 | n/a |
| IA/0001 | IA_13_a_Change in test proc. for active substance - minor change                       | 23/03/2007 | n/a |